Response of cardiac mast cells to atrial natriuretic peptide

David B Murray1, Jason D Gardner, Scott P Levick

  • 1Cell and Developmental Biology and Anatomy, School of Medicine, University of South Carolina, 6439 Garners Ferry Rd., Columbia, SC 29208, USA.

Insights

Atrial natriuretic peptide (ANP) does not trigger cardiac mast cell degranulation or cause adverse ventricular remodeling. This study found ANP is not responsible for the cardiac mast cell-mediated remodeling seen in chronic volume overload.

Area of Science:

  • Cardiovascular Physiology
  • Immunology
  • Cell Biology

Background:

  • Cardiac mast cell degranulation is linked to adverse ventricular remodeling during chronic volume overload.
  • Atrial natriuretic peptide (ANP) levels increase with chronic volume overload.

Purpose of the Study:

  • To determine if atrial natriuretic peptide (ANP) induces cardiac mast cell degranulation.
  • To investigate ANP's role in volume overload-induced ventricular remodeling.

Main Methods:

  • Assessed histamine release from peritoneal and cardiac mast cells stimulated by ANP.
  • Administered ANP to blood-perfused isolated rat hearts to measure mast cell activation.
  • Evaluated effects of ANP and natriuretic peptide receptor antagonism (anantin) on cardiac function, matrix metalloproteinase-2 (MMP-2) activity, and collagen in rats with aortocaval fistulas.

Main Results:

  • ANP induced histamine release from peritoneal mast cells but not isolated cardiac mast cells.
  • ANP infusion into isolated hearts did not significantly activate cardiac mast cells.
  • ANP did not alter cardiac function, MMP-2 activity, or collagen fraction.
  • Anantin treatment in volume-overloaded rats showed comparable MMP-2 increases and collagen reduction as controls, with no effect on cardiac function or hypertrophy.

Conclusions:

  • Atrial natriuretic peptide (ANP) is not a cardiac mast cell secretagogue.
  • ANP does not mediate adverse ventricular remodeling associated with cardiac mast cells during volume overload.

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Sympathetic Pathways: Collateral Ganglia and Adrenal Medulla01:27

Sympathetic Pathways: Collateral Ganglia and Adrenal Medulla

The sympathetic pathways of the collateral ganglia and adrenal medulla serve unique but interconnected roles in the sympathetic response.
Collateral Ganglia
Sympathetic preganglionic axons reach the collateral ganglia along the route of splanchnic nerves. These nerves bypass the sympathetic trunk and communicate with sympathetic postganglionic neurons housed in the prevertebral ganglia. These ganglia supply the organs of the abdominopelvic cavity.
The greater splanchnic nerve, formed by the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...